Skip to main content

ADVERTISEMENT

Oliver Sartor, MD

Oliver Sartor, MD, Mayo Clinic
Videos
10/11/2023
At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
At the 2023 EANM meeting, Oliver...
10/11/2023
Oncology
Oliver Sartor, MD, Mayo Clinic
Videos
10/25/2023
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress,...
10/25/2023
Oncology